Cel-Sci Corporation
As of Oct 22, 2026, Cel-Sci is in Stage 1, the basing phase, now in week 9 (since Aug 25, 2026). It closed at $1.61, 82.6% below its 52-week high and below its 200-day average, which is falling.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CVM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CVM among Biotechnology478th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …478 | CVM | Stage 1 · wk 9 | 10 | −4.2% |
Cel-Sci: quick answers
What stage is Cel-Sci in?
As of Oct 22, 2026, Cel-Sci (CVM) is in Stage 1, the basing phase. It entered Stage 1 on Aug 25, 2026 and is in week 9. What the four stages mean
Is Cel-Sci in an uptrend?
Not yet. Cel-Sci is in Stage 1, a base that can come before an uptrend. It trades 38.8% below its 200-day average, which is falling.
How far is Cel-Sci from its 52-week high?
Cel-Sci closed at $1.61 on Oct 22, 2026, 82.6% below its 52-week high of $9.27. Its 52-week low is $0.97.
How has Cel-Sci performed over the past year?
As of Oct 22, 2026, Cel-Sci is down 82.5% over the past year and down 68.7% so far in 2026.
Which sector and industry is Cel-Sci in?
Cel-Sci is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.